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Abstract — Botulism is a potentially lethal disease caused by one of seven homologous neurotoxic proteins usually produced by the
bacterium, Clostridium botulinum. This neuromuscular disorder occurs through an exquisite series of molecular events, ultimately
ending with the arrest of acetylcholine release and hence, flaccid paralysis. The development of vaccines that protect against botulism
dates back to the 1940s. Currently, a pentavalent vaccine that protects against BoNT serotypes A-E and a separate monovalent vaccine
that protects against BoNT serotype F are available as Investigational New Drugs. However, due to the numerous shortcomings
associated with the toxoid vaccines, several groups have efforts towards developing next-generation vaccines. Identifying a synthetic
peptide that harbors a neutralizing epitope is one approach to a BoNT vaccine, while another employs the use of a Venezuelan equine
encephalitis virus replicon vector to produce protective antigens in vivo against BoNT. The strategy used in our laboratory is to design
synthetic genes encoding non-toxic, carboxy-terminal fragments of the C. botulinum neurotoxins (rBoNT(HC)). The gene products are
expressed in the yeast, Pichia pastoris, and purified to greater than 98% with yields typically ranging from 200-500 mg per kg of wet
cells. Protective immunity to the purified products against high-level challenges of neurotoxin is elicited in mice and in non-human
primates. A pre-Investigational New Drug meeting was held with the Food and Drug Administration, and the next milestone for the
vaccine candidates will be clinical trials. © 2000 Société française de biochimie et biologie moléculaire / Éditions scientifiques et
médicales Elsevier SAS
botulinum neurotoxin / vaccine / C-fragment / purification / efficacy

1. Introduction
The toxins produced by the bacterium, Clostridium
botulinum, are the most lethal substances known and are
the causative agents of the disease, botulism. Indeed, a
single molecule can abolish the function of a nerve cell,
while a lethal dose is on the order of ng per kg of body
weight [1]. The botulinum neurotoxins (BoNT) are produced by one of seven structurally similar C. botulinum
serotypes, designated A to G. These toxins exert their
action by arresting the release of the neurotransmitter,
acetylcholine, at the neuromuscular junction [2–4]. Clinical manifestations of the disease are dominated by the
neurological signs and symptoms resulting from a toxininduced blockade of the voluntary motor and autonomic
cholinergic junctions. Symmetrical cranial nerve impairment affecting the bulbar musculature frequently marks
the onset of symptoms such as ptosis, ambiopia and/or
blurred vision, dysphonia, and a dry, sore throat. Flaccid
paralysis of the pharyngeal and laryngeal muscles gives
rise to dysphagia and dysarthria. If botulism is a consequence of ingesting improperly preserved foodstuffs con* Correspondence and reprints.
E-mail address: leonard.smith@det.amedd.army.mil (Leonard
A. Smith).

taminated with bacteria and their pre-formed toxins,
nausea, abdominal pain, vomiting, and diarrhea may often
precede or accompany the neurologic indications. As the
disease progresses, a descending paralysis ensues in which
the neck muscles, respiratory muscles, and muscles in the
extremities and trunk are affected. The paralysis of the
respiratory muscles leading to dyspnea or ventilatory
failure is the cause of death in a botulinum intoxication.
BoNT are initially synthesized as 150-kDa, single
polypeptide chain, precursor proteins which are posttranslationally nicked forming a dichain consisting of a
C-terminal 100-kDa heavy chain and a N-terminal 50-kDa
light chain. The dichain remains covalently attached by a
disulfide link [5, 6] but the extent of nicking varies from
completely nicked (serotype A) to completely non-nicked
(serotype E) (figure 1). The mechanism of nerve intoxication is accomplished through the interplay of three key
events, each of which is performed by a separate portion
of the neurotoxin molecule (see [7–9] for reviews). First,
the carboxy half of the heavy chain (fragment C or HC) is
required for receptor specific binding to cholinergic nerve
cells [10–12]. There is evidence suggesting that polysialogangliosides [13] or synaptotagmin [14, 15] could act as
receptors for the toxins but the data supporting a specific
receptor remain equivocal [16]. After binding, the toxin is
internalized into an endosome through receptor-mediated
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Figure 1. Schematic diagram of BoNT primary structures.
Protease nicking site distinguishes the light and heavy chains
which remain covalently associated by a disulfide link.

endocyctosis [17, 18]. The amino-terminal half of the
heavy chain (HN) is believed to participate in the translocation mechanism of the light chain across the endosomal
membrane [4, 19–22]. The low pH environment of the
endosome may trigger a conformational change in the
translocation domain, thus forming a channel for the light
chain. Alternatively, the receptor may assist the toxin in
transporting the light chain across the membrane. The
final event of intoxication involves the catalytic hydrolysis
of key synaptic vesicle proteins [3, 23–25] by the light
chain [3, 26]. The light chains are zinc-dependent endoproteases that selectively inactivate three essential proteins involved in the docking and fusion of acetylcholinecontaining synaptic vesicles to the plasma membrane. The
light chains of BoNT serotypes A, C1, and E cleave
SNAP-25 (synaptosomal-associated protein of 25 kDa)
[27–30]; serotypes B, D, F, and G cleave VAMP/
synaptobrevin (synaptic vesicle-associated membrane
protein) [31]; and serotype C1 cleaves syntaxin [32].
Inactivation of SNAP-25, VAMP, or syntaxin by BoNT
leads to an inability of the nerve cells to release acetylcholine, resulting in neuromuscular paralysis.
2. BoNT toxoid vaccines
Prophylactic and therapeutic countermeasures to botulism have been investigated since the 1940s. Inhibition of
BoNT action at any of the key steps of the process
outlined above could abolish the onset of botulism.
Currently, a pentavalent botulinum toxoid (PBT), against
serotypes A through E [33–36], is used to immunize
specific populations of at-risk individuals, i.e., scientists
and health care providers who handle BoNT, and our
armed forces, who may be subjected to weaponized forms
of the toxin.
The manufacture of PBT, by the Michigan Department
of Public Health (MDPH), took place in stages and over
many years. The fermentation, isolation, purification and
detoxification steps for each serotype took place in the late
1960s and early 1970s. The toxoid was manufactured by
initially culturing C. botulinum serotypes A-E to produce
crude preparations of neurotoxins. The toxins were separated from the culture fluid by acid precipitation overnight
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in the cold, then separated from the supernatant fluid by
filtration and/or centrifugation. The precipitated toxin was
washed, extracted, and filtered to remove any particulate
material. Toxins were again precipitated, filter-sterilized,
and detoxified by adding formalin. Residual formalin was
left in the vaccine products to ensure that the neurotoxins
remained non-toxic. Monovalent vaccines were then adsorbed to aluminum hydroxide and blended into a pentavalent vaccine. The monovalent bulks were completed
in 1971, and first packaged in 1978. Investigational New
Drug (IND) status was granted for the PBT under the
Centers for Disease Control’s IND 161 (at risk workers)
and under the United States Army’s Office of Surgeon
General IND 3723 (for military deployment). The MDPH
product was studied and used as an investigational vaccine
from 1979 until the present time.
An effort is ongoing on the part of the United States
Army to obtain Food and Drug Administration (FDA)
licensure for the PBT lots PBP003 and PBP004. For
licensure of the PBT, FDA required (1) that a pivotal
clinical trial be performed to reevaluate safety and assess
immunogenicity of the toxoid, and (2) that a new lot of
toxoid be manufactured to demonstrate reproducibility
and robustness of the manufacturing process, and consistency of the manufactured product. The final report on the
pivotal clinical study was expected in June 2000. This
study will have evaluated, in a significant number of
participants, the protective immunogenicity of all five
serotype vaccines with respect to their homologous neurotoxins. Results from this pivotal study and the status of
a new-generation, recombinant vaccine will be factors in
deciding whether to proceed with a new lot of toxoid.
Though serotypes A, B, and E are most associated with
botulism outbreaks in humans, type F has also been
diagnosed [37–39]. A separate monovalent toxoid vaccine
against BoNTF [40] was manufactured for the U.S. Army
by Porton Products Limited in cooperation with the
United Kingdom Governments Center for Applied Microbiology and Research (CAMR) in 1990. The vaccine
batch no. 002/90 was derived from pooling three production lots of C. botulinum F toxin. The harvested toxin
(i.e., by acid precipitation, tangential flow filtration, and
centrifugation) from each of three fermentation runs was
pooled, and the type F toxin extracted with sodium
phosphate buffer. After ribonuclease treatment, the toxin
was further purified by ammonium sulfate precipitation,
and repeated fractionation on fast liquid column chromatography on a fast flow Q Sepharose column. Unlike the
toxoid (estimated toxoid purity of 10%) [36], the purity of
the type F botulinum toxoid Lot no. 002/90 was greater
than 60% (IND 5077). The partially purified F toxin was
formalin-detoxified and adsorbed to aluminum hydroxide.
An IND application was filed with FDA in April 1993
to conduct a phase I clinical trial to evaluate the safety of
the botulinum F toxoid vaccine. The clinical study was
conducted by the Medical Division at the U.S. Army
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Medical Research Institute of Infectious Diseases under
IND 5077. The toxoid was well-tolerated in all of the 35
participants receiving the vaccine. Immunogenicity data
gathered on sera from the recipients of the vaccine
demonstrated that two doses of vaccine (10 µg per dose)
produced an antibody response considered protective by
the CDC guidelines (a titer > 0.02 IU/mL). Ninety percent
(18/20) of the volunteers seroconverted after two vaccinations and 100% (10/10) after three vaccinations [41].
A phase II clinical trial was conducted under IND 5077
at the University of Maryland Medical School (Baltimore,
MD) over 3 years (1995–1998) in 144 healthy adult
volunteers. The phase II trial was conducted to expand the
limited Army phase I trial and to identify a vaccination
schedule that was safe and maximally immunogenic for
volunteers. Administered (10 µg per dose) as a primary
series of three injections (i.e., at 0, 7, and 28 days; 0, 14,
and 42 days; and 0, 21, and 42 days), and as a booster
injection 12 months post primary series (if required), the
C. botulinum Type F toxoid was generally well-tolerated
and safe whether injected by the subcutaneous or intramuscular route. The C. botulinum Type F toxoid induced
significantly more immediate pain on injection than did
the licensed hepatitis B vaccine control, although the pain
was transient and tolerated (Dr. Robert Edelman, personal
communication).
Immunological response indicated that 61 to 83% of
the study subjects met the criteria for a booster dose at 1
year because of their low antitoxin levels (i.e., < 0.10
IU/mL) at 6 months. One hundred percent of the subjects
boosted at 1 year developed high concentrations of protective antitoxin by day 56 post-boost, and protective
levels (≥ 0.02 IU/mL) persisted for at least 360 days in all
subjects (Dr. Robert Edelman, personal communication).
Even though toxoid vaccines are available, there are
numerous shortcomings with their current use and ease of
production. First, because C. botulinum is a spore-former,
a dedicated facility is required to manufacture a toxinbased product. The requirement for a dedicated manufacturing facility is not trivial. It is extremely costly to
renovate and upgrade an existing facility or to build a new
one and then to maintain the facility in accordance with
current Good Manufacturing Practices (cGMP) to manufacture one vaccine. Second, the yields of toxin production from C. botulinum are relatively low. Third, the
toxoiding process involves handling large quantities of
toxin and thus is dangerous, and the added safety precautions increase the cost of manufacturing. Fourth, the
toxoid product for types A-E consists of a crude extract of
clostridial proteins that may influence immunogenicity or
reactivity of the vaccine, and the type F toxoid is only
partially purified (IND 5077). Fifth, because the toxoiding
process involves the use of formaldehyde, which inactivates the toxin, and residual levels of formaldehyde (not to
exceed 0.02%) are part of the product formulation to
prevent reactivation of the toxin, the vaccine is reactoge-
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nic. An additional component of the toxoid vaccines is the
preservative thimerosal (0.01%), which also increases the
reactogenicity of the product.
The development of a new-generation, recombinant
vaccine could alleviate many of the problems associated
with the toxoid. A recombinant vaccine would eliminate
the need for a dedicated manufacturing facility. Presently,
many cGMP facilities are in existence and available that
could manufacture a recombinant product. There would be
no need to culture large quantities of a hazardous toxinproducing bacterium. Production yields from a genetically
engineered product is expected to be high. Presumably,
there would be no need to treat the vaccine with formalin
if the recombinant vaccine candidate represented a fragment of the toxin. A fragment would not possess all three
functional domains (i.e., binding, internalization, catalytic) which are all required for its mechanism of action.
Recombinant products would be purer, less reactogenic,
and more fully characterized. Thus, the cost of a recombinant product would be expected to be much lower than
a toxoid because there would be no expenditures required
to support a dedicated facility, and the higher production
yields would reduce the cost of the vaccine product.
3. Other strategies for developing a BoNT vaccine
There are alternative approaches to developing vaccines against the botulinum neurotoxins that are currently
being pursued by several laboratories. We summarize two
of those strategies below.
The efforts in the laboratory of Atassi and coworkers
have focused on the development of a synthetic vaccine
against BoNT intoxication [42, 43]. The investigators
synthesized a series of overlapping 19-mer peptides that
spanned the entire HC region of BoNT serotype A (BoNT/
A). These peptides were thoroughly analyzed for their
ability to be recognized by anti-BoNT/A antibodies raised
in human, horse, and mouse. In addition to mapping the
epitopes using antibodies, the epitopes were mapped using
T-lymphocytes as well. The investigators have identified
which peptides elicit antibody and T-cell responses in two
different strains of mice (BALB/c and SJL) that crossreact with the HC region of BoNT/A. These experiments
provide the foundation for possibly developing a synthetic
vaccine that could protect against botulinum neurotoxin
intoxication.
Venezuelan equine encephalitis (VEE) virus replicon
vectors have emerged as an effective strategy for developing candidate vaccines. Pushko et al. have demonstrated that when a heterologous gene encoding influenza
hemagglutanin (HA) or the Lassa virus nucleocapsid (N)
is substituted for the VEE structural proteins followed by
transfection into eukaryotic cells, the replicon system can
express high levels of HA or N proteins [44]. When
packaged into virus-like particles, these replicons have
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also been found to induce potent immune responses in
inoculated animals against the heterologous proteins, and
to protect animals against challenge with the heterologous
virus. Similarly, Lee and coworkers introduced the gene
fragment encoding the nontoxic HC region of BoNTA into
the VEE virus replicon vector. This construct not only
yielded high levels of HC in BHK cells as judged by
immunofluorescence and Western analysis, but also protected mice against a 105 LD50 challenge of BoNTA (Lee
J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith
L.A., Smith J.F., in preparation).

4. Recombinant vaccines against BoNT
In 1984, Helting and Nau [45] demonstrated that
protein fragments generated from papain-digested tetanus
toxin (TeNT) elicited protective immunity in mice. A few
years later, Fairweather and coworkers [46] showed that
partially purified recombinant fragment C from tetanus
toxin (rTeNT(HC)) protected mice when challenged with
10 LD50 of tetanus toxin. Because of the high sequence
and structural homology that exists between the clostridial
neurotoxins produced by C. tetani and C. botulinum, we
applied this strategy to developing a vaccine to protect
against botulism.
We demonstrated early on that we could subclone
segments of the BoNTA gene and express these non-toxic
fragments in Escherichia coli [47]. We were then able to
vaccinate mice with the non-toxic recombinants and test
their ability to elicit protective immunity in vivo. Clones
pCBA2, pCBA3, and pCBA4 (gift from Nigel Minton)
containing overlapping gene fragments of the BoNTA
gene [48], were the source for templates used to produce
the various antigens to be examined. Smaller versions of
the gene fragments were constructed by cutting with
restriction enzymes. Specific gene segments were produced by PCR. Expressed products were identified by
SDS-PAGE and Western blot analyses, partially purified,
and used to vaccinate mice. Antigens representing various
regions from the three functional domains of the toxin
were analyzed for their ability to elicit protective antibodies in mice. Of all the fragments we and others [49–51]
tested, only one was able to completely protect mice. This
was the fragment located at the carboxy-terminus of the
toxin (∼50 kDa) designated as the fragment C region. Our
subsequent efforts to develop vaccine candidates to protect against BoNT forthwith focused exclusively on the
HC region.
One could imagine the most ideal recombinant BoNT
vaccine candidate would be the smallest, non-toxic fragment of the toxin capable of eliciting significant protective
immunity, while being completely devoid of any detectable biological property associated with its parent neurotoxin (i.e., receptor binding, translocation, and/or en-
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doproteolytic activity). One approach to a recombinant
BoNT vaccine has been proposed [52] which would
employ a mutated holotoxin as the immunogen. In this
appraoch, the endoproteolytic activity of the light chain
would be removed by altering the amino acid residues
required for zinc binding (H229 → G and H233 → N) and
the water molecule binding (E230 → T) [52]. The resultant
immunogen, however, would still retain binding and
internalization activities. We believed the retention of
those activities could be problematic in terms of their
effects on safety and the additional testing we might be
required to do to convince the Center for Biologics
Evaluation and Review (CBER) at FDA that this product
was safe. And indeed, at a pre-IND meeting on April 9,
1999, held to review the recombinant BoNT(HC) vaccines, a CBER panel voiced concern as to the potential of
our putative HC vaccine to cause adverse neurological
reactions or disorders due to its nature of binding to
specific receptors on cholinergic nerve cells. Although in
competition studies, BoNTA- and B(HC) vaccines did not
compete with the neurotoxin for receptor binding (unpublished data), the CBER panel recommended we do additional testing (e.g., Functional Observational Battery [53,
54] beyond the acute toxicology testing already performed
on these vaccine candidates).
5. Design of synthetic BoNT(HC) gene, construct,
and expression in Pichia pastoris
The yeast strain Pichia pastoris, originally developed
by the Phillips Petroleum Company, was chosen as a host
because of the high level of recombinant expression
exhibited by this system with other proteins [55–58].
Clare and coworkers [59] reported yields of 12 g/L of
TeNT(HC) when expressed in P. pastoris. Using P. pastoris would also eliminate the potential problems associated with inclusion bodies formed during expression in E.
coli, as well as the need to remove endotoxin.
Because of rare codons [60], and high adenine and
thymine (A+T)-rich base compositions [61] found in the
naturally-occuring clostridial DNA, it was necessary to
construct synthetic genes [57, 59, 61] to eliminate these
impediments to optimal expression in heterologous expression systems such as E. coli and yeast. We prepared
synthetic genes for the HC of BoNT with codon usage
specified by highly expressed genes in E. coli and yeast.
Genes designed and constructed using E. coli codon usage
[62] expressed full-length products in both E. coli and P.
pastoris, while genes designed and constructed using P.
pastoris codon usage [63] likewise, expressed proteins
with the expected molecular mass in both hosts.
In designing the length of the BoNT(HC) genes, there
was a question as to where the HC region of BoNT began,
because unlike TeNT, BoNTs do not possess a unique
papain cleavage site. It was critical that the expressed
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product properly fold into a conformation that would not
disrupt the neutralizing epitope(s). Also, if the HC folded
properly, the chance of expressing a soluble antigen would
increase. We believed the best strategy for meeting those
requirements would occur if the gene encoded a homologous region in BoNT(HC). Also, the crystal structures for
the TeNT binding domain [64] and the BoNTA [65] were
not available until 1997, thus deciding where the recombinant vaccine should begin was suggested by using
sequence alignments and theoretical secondary structural
analyses. The published three-dimensional structure of
BoNTA revealed that the topology of the HC was defined
by two sub-domains, an N-terminal jelly roll motif and a
C-terminal modified β-trefoil domain. There exists substantial sequence homology among the fragment C serotypes; however, sequence alignment of the final approximately 150 residues of the β-trefoil significantly deviates
from the homology [66]. Because there is very little
cross-reactivity among the serotypes, there is conjecture
that the final approximately 150 residues of the HC possess
the protective epitope(s) [67].
Synthetic genes encoding BoNT-A(HC), B(HC), and E
(HC), were initially inserted into the yeast secretion vector,
pPIC9K [68] and fused to the α-mating factor signal
sequence for secretion from the yeast cell into the medium. There are many heterologous proteins secreted from
yeast and this approach offered certain advantages over
intracellular expression, including the production of a
purer protein fraction with which to begin process development. However, secretion of HC proteins resulted in the
unwanted glycosylation of expressed products [47].
Therefore, the gene was placed in a vector that would
allow the product to be expressed intracellularly.
The synthetic genes were subsequently inserted into the
yeast expression vector, pHILD4 (for description see [69])
for intracellular expression. The expression cassette was
integrated into the chromosomal alcohol oxidase of P.
pastoris strain GS115 [59]. Yeast transformants expressing the selectable markers, histidine dehydrogenase [70]
and aminoglycoside phosphotransferase 3’ I [68], were
isolated. Clones were assessed by their ability to express
recombinant proteins with expected molecular masses as
judged by SDS-PAGE and Western blot analysis. Positive
clones were selected for growth in a fermentation reactor
under the control of methanol induction. The fermentation
process consisted of three phases: a batch phase where
pichia cells grew exclusively on glycerol, followed by a
fed-batch phase of decreasing glycerol, and finally a
fed-batch phase of increasing methanol. Typically, the
methanol induction phase was 10–70 h depending on the
antigen, yielding a final cell mass of approximately 60 g
dry cell weight per liter of fermentation broth. Fermentation conditions have been worked out for optimum yield
of HC for each of the serotypes [69, 71, 72].
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6. Process for purifying BoNT(HC) from Pichia
pastoris
At the time of this review, a bioprocess development
was completed for BoNT(HC) serotypes A, B, C1, and F
[69, 71–74] (Smith L.A., Byrne M.P., in preparation) and
a manufacturing process for serotype E is in development.
Purification streams for the vaccines are briefly discussed
below and outlined in figure 2. Because the ultimate
objective of this work is to produce a vaccine product
suitable for human use (i.e., highly-purified, safe, and
effective), our general purification strategy was to employ
conventional chromatographic techniques. Even though
separations may be accomplished at extremely high resolution with affinity chemistry, there remains an undesirable affect of hapten leaching from the resin. Therefore, an
extra step would be required to demonstrate that the
product is free of ligand. Furthermore, conventional chromatographic resins are more conducive for scale-up pilot
plant separations. As C-fragments lack catalytic activity
and any distinguishing chromaphores, purity and identity
of the HC throughout the process development were
monitored by SDS-PAGE and immunological (Western
blot and ELISA) detection methods.
Yeast cells were disrupted by using either a Gaulin
homogenizer or a microfluidizer device. With either technique, > 95% cell disruption was achieved as judged by
microscopy. The detergent, CHAPS, was incorporated into
the cracking buffers for serotypes A and C1 to facilitate
greater yield of product in the soluble fraction. After cell
disruption, it was critical that nucleic acids be effectively
removed from the soluble extract as they not only interact
strongly with BoNT(HC) (types A, E, and F) but also
saturate anion-exchange media (as is used in the first step
of the type C1 process). The nucleic acids were typically
removed by polyethylenimine (PEI) precipitation and/or
by diafiltering the soluble extract. For each serotype the
initial separation technique was cation-exchange chromatography with only type C1(HC) requiring anion-exchange
chromatography due to its low calculated isoelectric point
(pI) (5.3). Except for B(HC), the final polishing step was
hydrophobic interaction chromatography. The process for
type B employed a weak anion-exchange step to remove
the final impurities. Because of its neutral calculated pI
(7.1), type B was amenable to both anion and cation
chemistries without subjecting the antigen to extremes of
pH. The general use of ion-exchange and hydrophobic
interaction chromatographies was an effective strategy
because they provide separations based on complimentary
physical properties (i.e., electrostatic and hydrophobic
interactions). The resulting HC products were judged to be
> 98% pure as detected by SDS-PAGE and their yields
were generally 200-500 mg/kg of cells wet weight. A
typical cell yield (i.e., wet cell weight) from a 30-L
biorector was 6 kg of wet cell mass. Currently, the type
E(HC) purification process is being developed. A cation-
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Figure 2. Production and purification processes for BoNT(HC) serotypes A (A), B (B), C1 (C), and F (D) from Pichia pastoris are
shown on the left of each panel. SDS-PAGE of purified BoNT(HC) serotypes A, B, C1, and F are shown on the right of each panel.
Lane 1 shows the Novex (San Diego, CA, USA) protein standards.
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Figure 2. Continued.
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exchange separation will probably be incorporated as the
initial chromatography step while subsequent separation
techniques are yet to be determined. Yeast clones harboring the fragment C genes for the last two serotypes (i.e.,
rBoNTD(HC) and rBoNTG(HC)) have been isolated and
process development will begin after completion of rBoNTE(HC).
7. Potency, efficacy, and ELISA of BoNT(HC)
With any vaccine, the most important question is, how
safe and efficacious is the product? In our laboratory and
others, many studies have been performed addressing this
question, primarily using mice as the animal model, but
studies have been performed in non-human primates as
well [75]. In general, the BoNT(HC) are remarkably
efficacious antigens. For example, mice vaccinated with as
little as 1 µg of B(HC) were fully protected when challenged with as much as 106 mouse LD50 of BoNTB [47].
Mice vaccinated with three doses of vaccine remain
protected against a challenge of 106 mouse LD50 of
BoNTB 12 months post-vaccination. Similar long-term
protection was also observed in mice for the A serotype
vaccine (unpublished data).
One of the most important analyses of a drug product is
a potency test. Potency is the specific ability or capacity of
the product, as indicated by appropriate laboratory tests or
by adequately controlled clinical data obtained through
the administration of the product in the manner intended,
to affect the given result. The potency assay should be
relevant to its intended use, which for a vaccine, is the
ability to elicit protective immunity against disease. Our
potency assay (Hinz M.E., Smith T.J., Smith, L.A., submitted) involved the administration of an aluminum hydroxide (0.2% Alhydrogel)-adsorbed vaccine to seven
groups of mice (10 mice/group for statistical relevance), at
doses varying from sub-microgram (0.011 µg) to microgram (8.1 µg) amounts, in a single intramuscular (i.m.)
injection. Three weeks post vaccination, the mice were
actively challenged with 103 mouse LD50 of neurotoxin by
intraperitoneal (i.p.) injection. Figure 3 summarizes the
potency results for HC serotypes A, B, C1, and F. Each
antigen yielded a dose-response curve liberating ED50
values ranging from 0.089–0.25 µg/mouse. Full protection
was realized at a single vaccine dose of 2 µg/mouse with
each serotype except F, where 9 out of 10 survived a 103
mouse LD50 toxin challenge.
An efficacy study provides a thorough analysis of the
protective effectiveness of an antigen and can be performed in a variety of manners. Antigen dose amount,
number of vaccinations, and challenge levels are the three
primary parameters that can be investigated individually
in an efficacy study. Generally, any two of these parameters can vary in a given study. For example, animals
can be offered a range of antigen doses and then chal-

Figure 3. Dependence of mouse survival on a single dose of
purified HC. Mice (Cr1:CD-1(ICR)) were challenged with 103
i.p. LD50 of BoNT toxin 21 days after vaccination.

lenged with increasing amounts of toxin (e.g., 103, 104,
and 105 LD50), keeping the number of vaccinations
constant. Our procedure usually varied antigen dose
amount and number of vaccinations while subjecting the
animals to a constant high level challenge. Protective
efficacy results for HC serotypes A and B are presented in
table I. Clearly, the data reveal that protection increases
with increasing number of vaccinations. With three vaccinations of only 0.1 µg, 9 out of 10 mice (serotype A) and
12 out of 12 mice (serotype B) survived a challenge of 105
LD50 of toxin. Standardized efficacy protocols to provide
information on short and long-term immunity elicited by
the C1(HC) and F(HC) vaccines are currently in progress.
Human vaccine efficacy is normally addressed by
performing clinical trials in locations where the incidence
of disease is predictable and is sufficient to measure a
statistically significant reduction in the number of cases of

Table I. Efficacy of rBoNT(HC) vaccines
% survivala A(HC)
% survivalb B(HC)
Number
of
vaccinations
Number
of vaccinations
Vaccination
dose (µg)
1X
2X
3X
1X
2X
3X
0.01
0.1
0.5
1.0
2.0
5.0

0
20
40
70
80
NDc

60
50
90
100
100
ND

50
90
100
100
100
ND

0
33
ND
67
ND
100

17
83
ND
100
ND
100

58
100
ND
100
ND
100

a
Each group consisted of 10 mice (Cr1:CD-1(ICR)) which were
all challenged with 105 mouse LD50 BoNTA. b Each group
consisted of 12 mice (Cr1:CD-1(ICR)) which were all challenged with 105 mouse LD50 BoNTB. c ND, value not determined.
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Table II. Antibody ELISA titers and serum neutralization titers of mice after vaccination with rBoNT(HC).
BoNT serotype A(HC)
Antibody ELISA titersa
Serum neutralization titersb
No. vaccinations
No. vaccinations
Vaccination
dose (µg)
1X
2X
3X
1X
2X
3X
0.01
0.1
0.5
1.0
2.0
5.0

400
400
400
1600
1600
NDc

1600
1600
6400
6400
25600
ND

1600
25600
25600
25600
102400
ND

<0.16
<0.16
<0.21
<0.16
<0.16
ND

<0.16
0.40
1.28
1.28
13.31
ND

0.49
26.62
13.31
33.55
33.55
ND

BoNT serotype B(HC)
Antibody ELISA titersa
Serum neutralization titersb
No. vaccinations
No. vaccinations
1X
2X
3X
1X
2X
3X
100
1600
ND
6400
ND
25600

1600
25600
ND
25600
ND
100000

25600
100000
ND
100000
ND
100000

<0.10
0.18
ND
0.48
ND
0.99

<0.10
0.62
ND
1.52
ND
3.69

0.76
4.23
ND
13.66
ND
12.50

a
Pooled mouse serum (50 µL per mouse) from each group was initially diluted 1:100, then four-fold for serum ELISA titers. Titer is
reciprocal of the highest dilution having an OD405 greater than 0.2 AU after correcting for background. b Pooled mouse serum (50 µL
per mouse) from each group was initially diluted 1:8, then four-fold for serum neutralization titers in units of IU/mL. c ND, value not
determined.

disease. However, the limited and unpredictable appearance of botulism cases does not allow for the identification
of a candidate study population to evaluate the efficacy of
a BoNT vaccine by any route of exposure. There is no
possibility of a clinical trial where controlled challenge
studies could be conducted with a lethal substance in an
ethical manner. The ethical and practical obstacles to
obtaining direct evidence of human efficacy of a BoNT
vaccine led to the development of a human correlate of
clinical efficacy for the PBT. Indeed, an FDA advisory
panel, in addressing efficacy issues for bacterial vaccines
and toxoids, made the following statement (Federal Register, 1985): “For diseases in which immunity depends
upon specific antibodies which either neutralize toxin or
which opsonize bacteria and lead to their prompt destruction within phagocytes, induction of such antibodies
correlates well with protection, and the measurement of
such antibodies may reflect efficacy quite faithfully.”
For a BoNT vaccine, it is necessary that a correlation be
made between the antibodies elicited by the vaccine and
their ability to neutralize active toxin. This is accomplished by taking serial dilutions of sera from vaccinated
animals, mixing the sera with a constant amount of toxin,
and injecting the mixture back into other animals (e.g.,
mice). The amount of neutralizing antibodies can be
determined by the survival rate of the animals used in the
test. By definition, 1 international unit (IU) of antitoxin
neutralizes 104 mouse i.p. LD50 of toxin. There are
variations to this neutralization assay that can be more
tedious but more indicative of protective efficacy. After
antibodies are purified from the sera of vaccinated animals
and assayed, they are administered passively to other
animals, those animals are then challenged with a known
quantity of active toxin by a specified route of delivery
(e.g., by aerosol), and the survival rate observed.
We routinely performed mouse neutralization assays on
serum samples derived from the recombinant BoNT
vaccine efficacy studies to show the correlation between

antibody production and toxin neutralization (table II).
Additionally, we have assay development studies ongoing
to determine the correlation between an immunological
response detected by an ELISA (enzyme-linked immunosorbent assay) compared to the mouse neutralization
assay. An ELISA is, in most cases, an effective and
suitable means to analyze immunological responses to
antigens. We have developed a host of ELISAs aimed at
detecting BoNT and BoNT fragments for determining
serum and neutralization titers of vaccinated animals, for
identifying which purification fractions contain product,
and for measuring product at various stages of a purification process. Perhaps the greatest benefit an ELISA can
provide though, is the reduced use of animals during
product development and evaluation. If there exists a high
correlation between protection and serum titer, then titers
can be used as an alternative to actively challenging mice
with toxin. Serum ELISA titers measure the total antibody
response to a given antigen, but does not measure the
antibodies responsible for neutralizing the toxin.
Table II summarizes the serum ELISA titers and serum
neutralizing antibody results of the same mice that were
used in the efficacy study described above for HC serotypes A and B. The data depicted in table II represents
pooled serum from each animal within the group. Though
a strong correlation is observed between survival and
group ELISA titer data, a significantly higher correlation
between survival and individual serum ELISA titers exists. For serotype A(HC), 82 out of 83 mice with titers
≥1600 [73] survived toxin challenge and similarly for
serotype F(HC), all 34 mice with titers ≥100 [69] survived
toxin challenge.
8. Regulatory issues and requirements
The time and cost in developing prophylactic and
therapeutic drugs destined for human use are substantial.
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For this reason, it is critical to know and understand the
guidance documents and regulatory issues put forth from
one’s regulatory agency early in the discovery phase of the
product. Title 21 of U.S. Code of Federal Regulations (‘21
CFR’) states the purpose of GMPs is “to assure that all
pharmaceutical, biologic, diagnostic, and medical device
products meet all of the requirements of the Federal Food,
Drug, and Cosmetic Act as to safety, and efficacy and have
the identity and strength to meet the quality and purity
characteristics which they purport to have.” The expectation from FDA is that a recombinant vaccine shall be
well-characterized in terms of its purity, identity, efficacy,
potency, consistency, stability, and most importantly, its
safety. The goal of a manufacturing process is to produce
an adequate predetermined quantity of product at a predetermined level of quality (i.e., a product that meets
rigorous acceptance criteria for purity, identity, efficacy,
potency, consistency, stability, and safety). Because traditional biologic products (including vaccines) are prepared
from biological sources that exhibit inherent biological
variability, the ability of a manufacturer to prepare a safe
product consistently and reproducibly is a concern. In-line
processing data or in-process testing provide information
that the manufacturing process is consistent and reproducible. If the process is consistent and reproducible, there is
a high probability the product will be of the same high
quality each time it is manufactured.
Much of our work over the past 4 years has been
devoted to developing scaled-up manufacturing processes
for each HC vaccine, and the in-process and lot release
testing to validate the product’s quality. Detail information
on assay development and assay validation, genetic characterization of clones, in-process and lot release testing,
product stability testing (e.g., real time, reconstituted, and
accelerated stability), and formulation studies on the
vaccine candidates was beyond the scope of this review
and not provided. However, it should be realized that
extensive testing must be performed on the products if the
products are to be well-characterized and allowed into
clinical trials.
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